Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

216,031-216,060 of 319,975

filter-aware
15
The slide uses a diagonal timeline layout to represent product evolution.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
16
The 2023 figure is marked with an asterisk indicating revenue guidance.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
17
The chart shows a progression from negative margin to positive margin.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
18
The slide uses a bar chart to demonstrate financial discipline and outlines three key areas of investment.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Traction1 hit
19
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations Beat · Team1 hit
20
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
21
Hyperfine | Investor Presentation Deck | 22 slidesHyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
22
The slide serves as a bibliography of peer-reviewed research supporting the company's portable MRI technology.Hyperfine | Investor Presentation Deck | 22 slides · Hyperfine
Pitch deck Investor relations 1 hit
01
Slide 1
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
02
Immix Biopharma | Investor Presentation Deck | 58 slidesImmix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
03
The slide uses a numbered list format to present key value propositions.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Attention1 hit
04
The slide uses a hub-and-spoke diagram to illustrate the central problem of CAR-T neurotoxicity and its four primary negative outcomes.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
05
Includes a cartoon mascot at the bottom.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
06
The slide uses a visual comparison to highlight the safety advantage of NXC-201, specifically focusing on neurotoxicity and CRS duration.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
07
Uses a visual icon-grid to represent market expansion from 5% of hospitals to a much broader network.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
08
The slide uses a molecular biology diagram to illustrate the structural difference in the binding domain of the NXC-201 therapy compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
09
Includes comparative bar charts and flow cytometry data.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
10
The slide uses a comparative timeline/chart layout to contrast clinical outcomes of three different therapies.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Aha Moment1 hit
11
The chart demonstrates the efficacy of NXC-201 (formerly HBI0101) in clearing diseased cells.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
12
The slide uses a process flow diagram to connect cellular pathology to clinical symptoms in the heart, liver, and kidneys.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
13
Includes extensive source citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
14
The slide uses a table structure to contrast treatment outcomes and patient growth across three stages of multiple myeloma.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
15
The slide uses a visual comparison to highlight a 67% improvement in response rates for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
16
Includes FDA approval precedents in the footer to establish credibility.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
17
Includes detailed clinical trial citations in the footer.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
18
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
19
The slide uses a side-by-side comparison structure to explain two distinct but complementary technology platforms.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
20
The table uses a standard pharmaceutical pipeline format, categorizing by clinical vs preclinical status and highlighting specific regulatory and clinical trial milestones.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · Interest1 hit
21
Combines market sizing data with a 'Why Now' narrative supported by industry news clippings and a comparative efficacy table.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit
22
The slide uses a wave-like visual to represent market segments and their associated valuations.Immix Biopharma | Investor Presentation Deck | 58 slides · Immix Biopharma
Pitch deck Investor relations Beat · InterestLoop · Golden Circle1 hit